FDA Rejects Celgene ' s NDA for Ozanimod in MS FDA Rejects Celgene ' s NDA for Ozanimod in MS

In a ' refusal to file ' letter, the FDA determined that the nonclinical and clinical pharmacology sections in the ozanimod NDA were insufficient to allow a complete review.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news